Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm.

Change log
Rai, Shivam 
Grockowiak, Elodie 
Hansen, Nils 
Luque Paz, Damien 
Stoll, Cedric B 

Interleukin-1β (IL-1β) is a master regulator of inflammation. Increased activity of IL-1β has been implicated in various pathological conditions including myeloproliferative neoplasms (MPNs). Here we show that IL-1β serum levels and expression of IL-1 receptors on hematopoietic progenitors and stem cells correlate with JAK2-V617F mutant allele fraction in peripheral blood of patients with MPN. We show that the source of IL-1β overproduction in a mouse model of MPN are JAK2-V617F expressing hematopoietic cells. Knockout of IL-1β in hematopoietic cells of JAK2-V617F mice reduces inflammatory cytokines, prevents damage to nestin-positive niche cells and reduces megakaryopoiesis, resulting in decrease of myelofibrosis and osteosclerosis. Inhibition of IL-1β in JAK2-V617F mutant mice by anti-IL-1β antibody also reduces myelofibrosis and osteosclerosis and shows additive effects with ruxolitinib. These results suggest that inhibition of IL-1β with anti-IL-1β antibody alone or in combination with ruxolitinib could have beneficial effects on the clinical course in patients with myelofibrosis.

Animals, Interleukin-1beta, Janus Kinase 2, Mice, Mice, Knockout, Myeloproliferative Disorders, Neoplasms, Nitriles, Osteosclerosis, Primary Myelofibrosis, Pyrazoles, Pyrimidines
Journal Title
Nat Commun
Conference Name
Journal ISSN
Volume Title
Springer Science and Business Media LLC
Cancer Research UK (C61367/A26670)
European Research Council (648765)
MRC (MR/V005421/1)
Medical Research Council (MC_PC_17230)